Unveiling the occurrence of diabetic ketoacidosis with SGLT2 Inhibitors: need for vigilance and careful monitoring

Authors

  • Anjali Srikanth Mannava Department of Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
  • Samyuktha Harikrishnan Department of Medicine, College of Medicine, Gulf Medical University, Ajman, UAE
  • Swathi Srinivas Department of Medicine, Sri Ramachandra Institute of higher education and research, Chennai, Tamil Nadu, India
  • Sri Pranvi Boyapati Department of Medicine, Siddhartha Medical College, Vijayawada, Andhra Pradesh, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20231460

Abstract

With great interest, we have read the case report titled “Euglycemic diabetic ketoacidosis (DKA)-a rare side effect of sodium-glucose co-transporter-2 inhibitor in a patient of type 2 diabetes mellitus with left ventricular dysfunction: a case report” published in the international journal of advances in medicine.

Metrics

Metrics Loading ...

References

Kaur A, Singh P, Singh G, Mohan G, Chopra G, Singh R. Euglycemic diabetic ketoacidosis-A rare side effect of sodium-glucose co-transporter-2 inhibitor in a patient of type 2 diabetes mellitus with left ventricular dysfunction: A case report. Int J AdvMed. 2021;8(8):1232-4.

Tsushima Y, Lansang MC, Makin V. The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleveland Clin J Med. 2021;88(1):47-58.

Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: The double-edged sword of SGLT2 inhibitors? Diabetologia. 2023;66(1):23-32.

Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J Diabetes Investigation. 2016;7(2):135-8.

Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metabol. 2015;100(8):2849-52.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384-95.

Lizzo JM, Goyal A, Gupta V. Adult diabetic ketoacidosis. In StatPearls. StatPearls Publishing. 2023.

Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-93.

Jabbour SA, Frandsen KB. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2018;41(10):e147-8.

Misra S, Oliver NS. Diabetic ketoacidosis in adults. BMJ. 2015;351:h5660.

Downloads

Published

2023-05-25

How to Cite

Mannava, A. S., Harikrishnan, S., Srinivas, S., & Boyapati, S. P. (2023). Unveiling the occurrence of diabetic ketoacidosis with SGLT2 Inhibitors: need for vigilance and careful monitoring. International Journal of Advances in Medicine, 10(6), 496–497. https://doi.org/10.18203/2349-3933.ijam20231460

Issue

Section

Letter to the Editor